Novartis & Sanofi CEOs Urge EU to Raise Drug Prices to US Levels

Call for Higher Drug Prices in the EU

• 💡 Novartis CEO Vas Narasimhan and Sanofi leader Paul Hudson have urged the European Union to allow drug prices to rise to US levels.
• 📉 They argue that current European price controls and austerity measures are reducing market attractiveness and waning competitiveness in the biopharma sector.
• ⚠️ The uncertainty surrounding tariffs is also cited as a disincentive for investment within the EU.

Proposed Changes for EU Markets

• 📈 The pharmaceutical leaders advocate for the EU to set higher list prices for drugs.
• 💬 They also call for clear communication on spending targets for new medicines to reward innovation.
• 🌍 The current model of producing in Europe and exporting to the US is deemed unsustainable, and they want the EU to strengthen its domestic market.

Pharmaceutical Investment Trends

• 🇺🇸 In recent weeks, drug makers have pledged significant investments in the US, partly in response to tariffs and to boost domestic manufacturing.
• 💰 AstraZeneca announced a $50 billion investment in the US over the next 5 years, with Novartis, Eli Lilly, and Johnson & Johnson also making substantial recent investments.
• ⚖️ Meanwhile, the US administration is considering linking US medicine prices to lower amounts paid by other developed countries, despite the US currently paying the highest drug prices globally.